Form 4: CytoDyn Director Ndhlovu Receives Stock Options as Part of Annual Grant

Director Lishomwa C Ndhlovu of CytoDyn Inc. was granted 800,000 non-qualified stock options on October 28, 2024, as part of the annual grant for fiscal year 2025.

Summary

• Lishomwa C Ndhlovu, a director of CytoDyn Inc., received 800,000 non-qualified stock options on October 28, 2024.
• The exercise price of these options is $0.13.
• This grant represents the annual award for fiscal year 2025 and is consistent with the Issuer's 2012 Equity Incentive Plan, as amended.
• 266,664 shares vested immediately on the grant date.
• The remaining shares will vest in equal monthly installments from October 2024 through May 2025.
• Ndhlovu has also granted a Limited Power of Attorney effective February 1, 2024, to Jacob Lalezari, Mitchell Cohen, Tyler Blok, and Nathan Fox to execute Forms 3, 4, and 5 on their behalf.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance contributes to the company's success.
• The grant incentivizes the director, potentially benefiting employees through improved company performance.

Key Dates